Loading
Lynch syndrome tumours share predictable mutations the immune system can target. A vaccine in early trials could be tested to see if it prevents polyps and cancers in carriers.
Lynch syndrome tumours share predictable frameshift neoantigens the immune system can target, so this idea runs a randomised phase 2/3 of the Nouscom frameshift peptide vaccine Nous-209 in carriers, on a background of aspirin, with adenoma incidence at three years as the primary endpoint and colorectal cancer incidence as secondary. Nous-209 has phase 1b immunogenicity data in Lynch carriers, and carriers have high event rates that make prevention trials feasible. The test is a 600-carrier RCT. At early-clinical maturity it addresses the bottlenecks Inherited risk is mostly unidentified and Prevention we already have is not deployed, and relates to Cancer interception vaccines for high-risk carriers.
Because Lynch syndrome tumours make the same abnormal proteins in almost every patient, a single vaccine could in principle be given to carriers before cancer develops. This small trial showed the concept is safe and immunogenic; whether it prevents cancer requires the randomised trials now being planned.
One bottleneck page and 15 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares Cancer interception vaccines for high-risk carriers, First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers, National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Neoantigen.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Mismatch-repair deficient (MSI-high) colorectal cancer.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Prevention we already have is not deployed.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, Prevention we already have is not deployed.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.